0.722
Schlusskurs vom Vortag:
$0.7691
Offen:
$0.751
24-Stunden-Volumen:
552.27K
Relative Volume:
1.32
Marktkapitalisierung:
$66.78M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-0.4912
EPS:
-1.47
Netto-Cashflow:
$-38.94M
1W Leistung:
-9.54%
1M Leistung:
+23.46%
6M Leistung:
+0.80%
1J Leistung:
-89.77%
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Vergleichen Sie VRCA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VRCA
Verrica Pharmaceuticals Inc
|
0.722 | 73.82M | 5.12M | -67.00M | -38.94M | -1.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-07-25 | Hochstufung | Needham | Hold → Buy |
2023-03-22 | Eingeleitet | Jefferies | Buy |
2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
2020-06-24 | Eingeleitet | Northland Capital | Outperform |
2020-03-24 | Eingeleitet | Needham | Buy |
2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity capital appreciation - jammulinksnews.com
What drives Verrica Pharmaceuticals Inc. stock priceFree Predictions - jammulinksnews.com
Is Verrica Pharmaceuticals Inc. a good long term investmentHigh-impact investment strategies - jammulinksnews.com
What analysts say about Verrica Pharmaceuticals Inc. stockMassive wealth growth - PrintWeekIndia
Published on: 2025-07-19 07:38:47 - jammulinksnews.com
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialAnalyst Grade Signals - Newser
What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser
What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com
How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus
Verrica Pharmaceuticals Receives Milestone Payments and Initiates Global Phase 3 Trial for YCANTH® Treatment of Common Warts - Quiver Quantitative
Verrica to receive $18 million in milestone payments from Torii in 2025 - Investing.com UK
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World
Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st
Verrica Pharmaceuticals amends credit agreement By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed - TipRanks
Verrica Pharmaceuticals amends credit agreement - Investing.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% – Here’s Why - Defense World
Verrica Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):